GPCRdb

Ligand source activities (1 row/activity)

Potency
Affinity

Get vendors

Ligands (move mouse cursor over ligand name to see structure)					Receptor	Activity									Chemical information
Sel. page	Common name	GPCRdb ID	Reference ligand	Vendors	Species	Assay Type	Activity Type	Activity Relation	Activity Value	p-value (-log)	Fold selectivity	Tested GPCRs	Assay Description	Source	Mol weight	Rot Bonds	H don	H acc	LogP	Smiles	DOI
	CHEMBL3102930	213497	None	0	Human	Functional	pEC50	=	10.3	10.3	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@]1(C)CCCC/C=C\CCCC[C@](C)(NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	168299476	192855	None	0	Human	Functional	pEC50	=	10.2	10.2	-1	3	Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4660	165	74	67	-19.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C(C)C)C(C)C)C(C)C)[C@@H](C)O	10.1021/acs.jmedchem.0c01396
	CHEMBL5220770	192855	None	0	Human	Functional	pEC50	=	10.2	10.2	-1	3	Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4660	165	74	67	-19.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(N)=O)C(C)C)C(C)C)C(C)C)[C@@H](C)O	10.1021/acs.jmedchem.0c01396
	CHEMBL4294827	215993	None	0	Human	Functional	pEC50	=	10.1	10.1	2	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H]1CNC[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)NC(CC(N)=O)CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)O	nan
	CHEMBL1893324	211519	None	20	Human	Functional	pEC50	=	10.1	10.1	-1	3	Agonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAgonist activity at VPAC2 in human SH-SY5Y cells assessed as cAMP accumulation incubated for 60 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(N)=O	10.1021/acs.jmedchem.0c01396
	2263	257	None	0	Human	Functional	pEC50	=	10.1	10.1	-1	3	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		None	10.1021/jm0609059
	44566111	257	None	0	Human	Functional	pEC50	=	10.1	10.1	-1	3	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		None	10.1021/jm0609059
	CHEMBL219499	257	None	0	Human	Functional	pEC50	=	10.1	10.1	-1	3	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		None	10.1021/jm0609059
	CHEMBL3102924	213491	None	0	Human	Functional	pEC50	=	10	10.0	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL3102925	213492	None	0	Human	Functional	pEC50	=	10.0	10.0	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CCC(=O)NCCCC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(C)C	10.1021/ml400257h
	CHEMBL3102919	213486	None	0	Human	Functional	pEC50	=	9.9	9.9	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL4277441	215832	None	0	Human	Functional	pEC50	=	9.7	9.7	1202	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	1152	3995	None	15	Human	Functional	pEC50	=	9.7	9.7	-3	8	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	16129679	3995	None	15	Human	Functional	pEC50	=	9.7	9.7	-3	8	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	53395115	3995	None	15	Human	Functional	pEC50	=	9.7	9.7	-3	8	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	91898389	3995	None	15	Human	Functional	pEC50	=	9.7	9.7	-3	8	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL1981592	3995	None	15	Human	Functional	pEC50	=	9.7	9.7	-3	8	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL3102922	213489	None	0	Human	Functional	pEC50	=	9.7	9.7	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL3102929	213496	None	0	Human	Functional	pEC50	=	9.7	9.7	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL3102931	213498	None	0	Human	Functional	pEC50	=	9.5	9.5	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@]1(C)CCCC/C=C\CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL3102921	213488	None	0	Human	Functional	pEC50	=	9.4	9.4	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL3105020	213530	None	0	Human	Functional	pEC50	=	9.4	9.4	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@]1(C)CCCC/C=C\CCCC[C@@](C)(C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC1=O)C(C)C	10.1021/ml400257h
	CHEMBL4291119	215967	None	0	Human	Functional	pEC50	=	9.4	9.4	22	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(CCCCN)CC(=O)NCC(=O)NCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4277799	215841	None	0	Human	Functional	pEC50	=	9.3	9.3	977	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4285873	215920	None	0	Human	Functional	pEC50	=	9.2	9.2	-	1	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL440082	216321	None	0	Human	Functional	pEC50	=	9.2	9.2	-	1	Activity at human VPAC2 receptor in CHO cells by measuring cAMP accumulationActivity at human VPAC2 receptor in CHO cells by measuring cAMP accumulation	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)O	10.1021/jm0609059
	CHEMBL4282016	215889	None	0	Human	Functional	pEC50	=	9.2	9.2	204	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O	nan
	CHEMBL4281547	215882	None	0	Human	Functional	pEC50	=	9.1	9.1	-	1	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4277870	215842	None	0	Human	Functional	pEC50	=	9.1	9.1	1659	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4294951	215995	None	0	Human	Functional	pEC50	=	9.0	9.0	-	1	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4289726	215948	None	0	Human	Functional	pEC50	=	9.0	9.0	-	1	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)NC(CC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)NCCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)Cc1ccc(O)cc1)[C@@H](C)O	nan
	CHEMBL3102923	213490	None	0	Human	Functional	pEC50	=	8.9	8.9	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CCCCNC(=O)CC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc2cnc[nH]2)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N1)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O	10.1021/ml400257h
	CHEMBL4291903	215972	None	0	Human	Functional	pEC50	=	8.9	8.9	660	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)NC(CC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(CC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)Cc1ccc(O)cc1)[C@@H](C)O	nan
	CHEMBL4276843	215828	None	0	Human	Functional	pEC50	=	8.9	8.9	-	1	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(CC(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4286419	215924	None	0	Human	Functional	pEC50	=	8.9	8.9	234	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4282364	215892	None	0	Human	Functional	pEC50	=	8.9	8.9	1071	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NC(CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL3102926	213493	None	0	Human	Functional	pEC50	=	8.9	8.9	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@](C)(CCCC=C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C	10.1021/ml400257h
	CHEMBL4283432	215901	None	0	Human	Functional	pEC50	=	8.9	8.9	-	1	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCNC(=N)N)CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL3102927	213494	None	0	Human	Functional	pEC50	=	8.8	8.8	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@](C)(CCCC=C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)C(C)C	10.1021/ml400257h
	CHEMBL3105019	213529	None	0	Human	Functional	pEC50	=	8.8	8.8	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@]1(C)CCCC/C=C\CCCC[C@@](C)(C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc2ccc(O)cc2)NC1=O)C(C)C	10.1021/ml400257h
	CHEMBL4294843	215994	None	0	Human	Functional	pEC50	=	7.0	7.0	-11	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)NC(CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)CC(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4281814	215885	None	0	Human	Functional	pEC50	=	6.6	6.6	-58	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4284858	215910	None	0	Human	Functional	pEC50	=	8.5	8.5	-	1	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)NC(C)(C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL4287451	215930	None	0	Human	Functional	pEC50	=	8.5	8.5	426	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)NC(CC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(N)=O)CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)NC(CCC(N)=O)CC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C	nan
	CHEMBL3102928	213495	None	0	Human	Functional	pEC50	=	8.4	8.4	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		C=CCCC[C@](C)(NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@](C)(CCCC=C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)[C@@H](C)CC	10.1021/ml400257h
	CHEMBL4280273	215866	None	0	Human	Functional	pEC50	=	6.5	6.5	-	1	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4277709	215838	None	0	Human	Functional	pEC50	=	5.3	5.3	-870	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4278228	215849	None	0	Human	Functional	pEC50	=	8.3	8.3	-	1	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H]1CNC[C@@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H]1CCC[C@@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O	nan
	CHEMBL4281905	215887	None	0	Human	Functional	pEC50	=	7.3	7.3	1	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4285866	215919	None	0	Human	Functional	pEC50	=	6.3	6.3	-	1	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)CC(CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL3102920	213487	None	0	Human	Functional	pEC50	=	8.2	8.2	-	1	Agonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assayAgonist activity at human VPAC2 expressed in CHO Flp-in cells assessed as accumulation of cAMP after 30 mins by TR-FRET assay	ChEMBL		None	None	None		None	10.1021/ml400257h
	CHEMBL4277783	215840	None	0	Human	Functional	pEC50	=	6.2	6.2	1	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)CC(NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)CC(CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4284839	215909	None	0	Human	Functional	pEC50	=	6.1	6.1	-11	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)CC(CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4280734	215870	None	0	Human	Functional	pEC50	=	7.1	7.1	-223	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	CHEMBL4284961	215912	None	0	Human	Functional	pEC50	=	7.0	7.0	9	2	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC(C)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1CNC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)CC(Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]1CCC[C@@H]1NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)NC(CCCCN)CC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)NCCC(=O)N[C@H](C(=O)O)[C@@H](C)O	nan
	CHEMBL4278811	215853	None	0	Human	Functional	pEC50	=	6	6.0	-	1	Agonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assayAgonist activity at human VIPR2 expressed in CHOK1 cells assessed as intracellular cAMP accumulation after 60 mins by PathHunter assay	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)CC(CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CC(CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CC(NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CC(CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)CC(NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(C)O)C(C)C)C(=O)NC(CC(=O)N[C@@H](CC(N)=O)C(=O)O)CC(C)C	nan
	11570626	2550	None	32	Human	Functional	pIC50	=	4.9	4.9	-794	8	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	9135	2550	None	32	Human	Functional	pIC50	=	4.9	4.9	-794	8	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	CHEMBL1933349	2550	None	32	Human	Functional	pIC50	=	4.9	4.9	-794	8	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	DB12044	2550	None	32	Human	Functional	pIC50	=	4.9	4.9	-794	8	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2c(c1)ccc(c2)c1cc(nn1[C@H](c1ccc(cc1)C(=O)NCCC(=O)O)C)c1cc(Cl)cc(c1)Cl	10.1021/jm300579z
	60170971	81432	None	0	Human	Functional	pIC50	=	5.8	5.8	-186	3	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4ccc(Cl)c(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	CHEMBL2159348	81432	None	0	Human	Functional	pIC50	=	5.8	5.8	-186	3	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4ccc(Cl)c(Cl)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	60170970	81431	None	0	Human	Functional	pIC50	=	5.6	5.6	-281	4	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4cc(Cl)ccc4Cl)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	CHEMBL2159347	81431	None	0	Human	Functional	pIC50	=	5.6	5.6	-281	4	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	587	9	2	5	7.5	COc1ccc2cc(-c3cc(-c4cc(Cl)ccc4Cl)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	60171059	81433	None	0	Human	Functional	pIC50	=	5.6	5.6	-794	4	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	621	9	2	5	7.9	COc1ccc2cc(-c3cc(-c4cc(Cl)cc(C(F)(F)F)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	CHEMBL2159349	81433	None	0	Human	Functional	pIC50	=	5.6	5.6	-794	4	Antagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counterAntagonist activity at human VPAC2 expressed in CHO cells assessed as inhibition of glucagon-induced cAMP accumulation preincubated for 30 mins prior to glucagon challenge measured after 30 mins post glucagon challenge by liquid scintillation counter	ChEMBL	621	9	2	5	7.9	COc1ccc2cc(-c3cc(-c4cc(Cl)cc(C(F)(F)F)c4)nn3[C@@H](C)c3ccc(C(=O)NCCC(=O)O)cc3)ccc2c1	10.1021/jm300579z
	90154832	153208	None	0	Human	Functional	pIC50	=	5.4	5.4	-	1	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	CHEMBL3976408	153208	None	0	Human	Functional	pIC50	=	5.4	5.4	-	1	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced cAMP accumulation incubated for 30 mins by HTRF assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	168298339	192818	None	0	Human	Functional	pIC50	=	8.4	8.4	-1	3	Antagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAntagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4137	147	67	59	-16.2	CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](CCS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C	10.1021/acs.jmedchem.0c01396
	CHEMBL5219662	192818	None	0	Human	Functional	pIC50	=	8.4	8.4	-1	3	Antagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assayAntagonist activity at VPAC2 in human SH-SY5Y cells assessed as inhibition of PACAP38-induced cAMP accumulation pre-incubated for 30 mins followed by agonist addition and measured after 75 mins by Eu-cAMP tracer based LANCE ultra cAMP assay	ChEMBL	4137	147	67	59	-16.2	CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](CCS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc1ccccc1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O)C(C)C)C(C)C	10.1021/acs.jmedchem.0c01396
	1152	3995	None	15	Human	Functional	pEC50	=	7.3	7.3	-3	8	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	16129679	3995	None	15	Human	Functional	pEC50	=	7.3	7.3	-3	8	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	53395115	3995	None	15	Human	Functional	pEC50	=	7.3	7.3	-3	8	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	91898389	3995	None	15	Human	Functional	pEC50	=	7.3	7.3	-3	8	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	CHEMBL1981592	3995	None	15	Human	Functional	pEC50	=	7.3	7.3	-3	8	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	16133238	2990	None	0	Human	Functional	pEC50	=	7.6	7.6	-85	6	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2257	2990	None	0	Human	Functional	pEC50	=	7.6	7.6	-85	6	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	44134520	2990	None	0	Human	Functional	pEC50	=	7.6	7.6	-85	6	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2258	2991	None	0	Human	Functional	pEC50	=	7.7	7.7	-17	4	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	1152	3995	None	15	Human	Functional	pEC50	=	7.8	7.8	-3	8	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	16129679	3995	None	15	Human	Functional	pEC50	=	7.8	7.8	-3	8	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	53395115	3995	None	15	Human	Functional	pEC50	=	7.8	7.8	-3	8	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	91898389	3995	None	15	Human	Functional	pEC50	=	7.8	7.8	-3	8	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	CHEMBL1981592	3995	None	15	Human	Functional	pEC50	=	7.8	7.8	-3	8	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	2272	3078	None	0	Human	Functional	pEC50	=	8.3	8.3	14	3	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2259	3346	None	0	Human	Functional	pEC50	=	8.3	8.3	190	4	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	1152	3995	None	15	Human	Functional	pEC50	=	9.2	9.2	-3	8	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	16129679	3995	None	15	Human	Functional	pEC50	=	9.2	9.2	-3	8	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	53395115	3995	None	15	Human	Functional	pEC50	=	9.2	9.2	-3	8	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	91898389	3995	None	15	Human	Functional	pEC50	=	9.2	9.2	-3	8	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	CHEMBL1981592	3995	None	15	Human	Functional	pEC50	=	9.2	9.2	-3	8	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2258	2991	None	0	Human	Functional	pEC50	=	9.3	9.3	-17	4	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	129887154	583	None	0	Human	Functional	pEC50	=	9.4	9.4	177	3	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	155817438	583	None	0	Human	Functional	pEC50	=	9.4	9.4	177	3	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16214732	583	None	0	Human	Functional	pEC50	=	9.4	9.4	177	3	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2269	583	None	0	Human	Functional	pEC50	=	9.4	9.4	177	3	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2281	583	None	0	Human	Functional	pEC50	=	9.4	9.4	177	3	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16133238	2990	None	0	Human	Functional	pEC50	=	9.4	9.4	-85	6	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2257	2990	None	0	Human	Functional	pEC50	=	9.4	9.4	-85	6	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	44134520	2990	None	0	Human	Functional	pEC50	=	9.4	9.4	-85	6	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2272	3078	None	0	Human	Functional	pEC50	=	8.4	8.4	14	3	inhibition of calcium influx stimulated by 30nM VIP in CHO cells stably expressing recombinant receptorinhibition of calcium influx stimulated by 30nM VIP in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2278	328	None	0	Human	Functional	pEC50	=	5.9	5.9	-4168	3	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	1152	3995	None	15	Human	Functional	pEC50	=	7.9	7.9	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	16129679	3995	None	15	Human	Functional	pEC50	=	7.9	7.9	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	53395115	3995	None	15	Human	Functional	pEC50	=	7.9	7.9	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	91898389	3995	None	15	Human	Functional	pEC50	=	7.9	7.9	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	CHEMBL1981592	3995	None	15	Human	Functional	pEC50	=	7.9	7.9	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	16133238	2990	None	0	Human	Functional	pEC50	=	8.4	8.4	-85	6	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2257	2990	None	0	Human	Functional	pEC50	=	8.4	8.4	-85	6	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	44134520	2990	None	0	Human	Functional	pEC50	=	8.4	8.4	-85	6	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2276	3345	None	0	Human	Functional	pEC50	=	8.5	8.5	316	2	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	1152	3995	None	15	Human	Functional	pEC50	=	8.5	8.5	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	16129679	3995	None	15	Human	Functional	pEC50	=	8.5	8.5	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	53395115	3995	None	15	Human	Functional	pEC50	=	8.5	8.5	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	91898389	3995	None	15	Human	Functional	pEC50	=	8.5	8.5	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	CHEMBL1981592	3995	None	15	Human	Functional	pEC50	=	8.5	8.5	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2259	3346	None	0	Human	Functional	pEC50	=	8.7	8.7	190	4	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	1152	3995	None	15	Human	Functional	pEC50	=	9.3	9.3	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	16129679	3995	None	15	Human	Functional	pEC50	=	9.3	9.3	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	53395115	3995	None	15	Human	Functional	pEC50	=	9.3	9.3	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	91898389	3995	None	15	Human	Functional	pEC50	=	9.3	9.3	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	CHEMBL1981592	3995	None	15	Human	Functional	pEC50	=	9.3	9.3	-3	8	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	2278	328	None	0	Human	Functional	pEC50	>	5	5.0	-4168	3	calcium influx in CHO cells stably expressing recombinant receptorcalcium influx in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	2278	328	None	0	Human	Functional	pEC50	>	5	5.0	-4168	3	cyclic AMP formation in CHO cells stably expressing recombinant receptorcyclic AMP formation in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633
	3842	2436	None	0	Human	Functional	pEC50	>	6	6.0	-1584	5	stimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptorstimulation of cyclic AMP formation in CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2272	3078	None	0	Human	Functional	pIC50	=	7.6	7.6	14	3	inhibition of cyclic AMP formation stimulated by 0.3nM VIP in CHO cells stably expressing recombinant receptorinhibition of cyclic AMP formation stimulated by 0.3nM VIP in CHO cells stably expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	16930633

Get vendors

Ligands (move mouse cursor over ligand name to see structure)					Receptor	Activity									Chemical information
Sel. page	Common name	GPCRdb ID	Reference ligand	Vendors	Species	Assay Type	Activity Type	Activity Relation	Activity Value	p-value (-log)	Fold selectivity	Tested GPCRs	Assay Description	Source	Mol weight	Rot Bonds	H don	H acc	LogP	Smiles	DOI
	CHEMBL524852	218111	None	7	Human	Binding	pIC50	=	8.0	8.0	-	0	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	118334911	144404	None	0	Human	Binding	pIC50	=	5	5.0	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	534	10	4	5	2.8	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)CCC2	nan
	CHEMBL3905363	144404	None	0	Human	Binding	pIC50	=	5	5.0	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	534	10	4	5	2.8	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)CCC2	nan
	73890927	148983	None	0	Human	Binding	pIC50	=	6.0	6.0	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	524	11	4	6	2.4	COc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3941654	148983	None	0	Human	Binding	pIC50	=	6.0	6.0	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	524	11	4	6	2.4	COc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334840	148618	None	0	Human	Binding	pIC50	=	6.0	6.0	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	11	4	5	2.9	CCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3938565	148618	None	0	Human	Binding	pIC50	=	6.0	6.0	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	11	4	5	2.9	CCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334843	149340	None	0	Human	Binding	pIC50	=	5.9	5.9	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	508	10	4	5	2.7	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3944350	149340	None	0	Human	Binding	pIC50	=	5.9	5.9	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	508	10	4	5	2.7	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	2263	257	None	0	Human	Binding	pIC50	=	7.9	7.9	-	1	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		None	10.1021/jm0609059
	44566111	257	None	0	Human	Binding	pIC50	=	7.9	7.9	-	1	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		None	10.1021/jm0609059
	CHEMBL219499	257	None	0	Human	Binding	pIC50	=	7.9	7.9	-	1	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		None	10.1021/jm0609059
	90154832	153208	None	0	Human	Binding	pIC50	=	5.9	5.9	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	CHEMBL3976408	153208	None	0	Human	Binding	pIC50	=	5.9	5.9	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	118334841	153610	None	0	Human	Binding	pIC50	=	5.9	5.9	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	519	10	4	6	2.2	N#Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3979900	153610	None	0	Human	Binding	pIC50	=	5.9	5.9	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	519	10	4	6	2.2	N#Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334918	148940	None	0	Human	Binding	pIC50	=	4.9	4.9	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	10	4	5	3.0	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1C	nan
	CHEMBL3941270	148940	None	0	Human	Binding	pIC50	=	4.9	4.9	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	522	10	4	5	3.0	Cc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1C	nan
	118334912	154411	None	0	Human	Binding	pIC50	=	4.9	4.9	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	572	11	4	7	1.8	CS(=O)(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3986723	154411	None	0	Human	Binding	pIC50	=	4.9	4.9	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	572	11	4	7	1.8	CS(=O)(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334831	147204	None	0	Human	Binding	pIC50	=	6.7	6.7	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
	CHEMBL3927475	147204	None	0	Human	Binding	pIC50	=	6.7	6.7	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
	CHEMBL507480	216823	None	0	Human	Binding	pIC50	=	7.6	7.6	-	0	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(-c2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	90154832	153208	None	0	Human	Binding	pIC50	=	5.6	5.6	-	0	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	CHEMBL3976408	153208	None	0	Human	Binding	pIC50	=	5.6	5.6	-	0	Antagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assayAntagonist activity at human VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced beta-arrestin 2 binding incubated for 2 hrs by beta-galactosidase assay	ChEMBL	539	11	4	7	2.3	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc([N+](=O)[O-])cc1	nan
	118334842	153941	None	0	Human	Binding	pIC50	=	5.6	5.6	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	562	10	4	5	3.4	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(F)(F)F)cc1	nan
	CHEMBL3982797	153941	None	0	Human	Binding	pIC50	=	5.6	5.6	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	562	10	4	5	3.4	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(F)(F)F)cc1	nan
	CHEMBL440082	216321	None	0	Human	Binding	pIC50	=	7.6	7.6	-	0	Displacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cellsDisplacement of [125I]PACAP27 from human VPAC2 receptor expressed in CHO cells	ChEMBL		None	None	None		CC[C@H](C)[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(C)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)O	10.1021/jm0609059
	118334830	154334	None	0	Human	Binding	pIC50	=	6.6	6.6	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	528	10	4	5	3.0	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
	CHEMBL3986225	154334	None	0	Human	Binding	pIC50	=	6.6	6.6	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	528	10	4	5	3.0	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
	118334834	152400	None	0	Human	Binding	pIC50	=	5.5	5.5	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	5	3.5	CC(C)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3969613	152400	None	0	Human	Binding	pIC50	=	5.5	5.5	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	5	3.5	CC(C)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	127035881	136572	None	0	Human	Binding	pIC50	=	7.4	7.4	-	0	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	CHEMBL3736134	136572	None	0	Human	Binding	pIC50	=	7.4	7.4	-	0	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	127035881	136572	None	0	Human	Binding	pIC50	=	7.4	7.4	-	0	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	CHEMBL3736134	136572	None	0	Human	Binding	pIC50	=	7.4	7.4	-	0	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3264	105	48	45	-10.6	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccc(F)cc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	90154607	153893	None	0	Human	Binding	pIC50	=	5.4	5.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCO2	nan
	CHEMBL3982346	153893	None	0	Human	Binding	pIC50	=	5.4	5.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	10	4	7	2.1	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCO2	nan
	118334924	147225	None	0	Human	Binding	pIC50	=	5.4	5.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	542	11	3	5	3.7	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
	CHEMBL3927669	147225	None	0	Human	Binding	pIC50	=	5.4	5.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	542	11	3	5	3.7	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(Cl)cc1	nan
	118334910	144736	None	0	Human	Binding	pIC50	=	4.4	4.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	11	5	6	2.4	CC(O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3908152	144736	None	0	Human	Binding	pIC50	=	4.4	4.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	538	11	5	6	2.4	CC(O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334914	151448	None	0	Human	Binding	pIC50	=	5.4	5.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	12	4	5	3.3	CCCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3961248	151448	None	0	Human	Binding	pIC50	=	5.4	5.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	12	4	5	3.3	CCCc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334919	153624	None	0	Human	Binding	pIC50	=	5.4	5.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	13	4	6	3.1	CCCOc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3980013	153624	None	0	Human	Binding	pIC50	=	5.4	5.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	552	13	4	6	3.1	CCCOc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	73890939	152920	None	0	Human	Binding	pIC50	=	6.4	6.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	6	2.6	CC(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3973956	152920	None	0	Human	Binding	pIC50	=	6.4	6.4	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	536	11	4	6	2.6	CC(=O)c1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334917	151292	None	0	Human	Binding	pIC50	=	4.3	4.3	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	13	4	6	3.5	CCC(C)Oc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	CHEMBL3959870	151292	None	0	Human	Binding	pIC50	=	4.3	4.3	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	13	4	6	3.5	CCC(C)Oc1ccc(S(=O)(=O)NC[C@@H](O)C[C@@H](Cc2ccccc2)C(=O)N[C@H]2c3ccccc3C[C@H]2O)cc1	nan
	118334925	142476	None	0	Human	Binding	pIC50	=	5.3	5.3	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	550	12	3	6	3.2	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(C)=O)cc1	nan
	CHEMBL3889643	142476	None	0	Human	Binding	pIC50	=	5.3	5.3	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	550	12	3	6	3.2	CO[C@@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(C(C)=O)cc1	nan
	127034614	136590	None	0	Human	Binding	pIC50	=	7.3	7.3	-	0	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	CHEMBL3736230	136590	None	0	Human	Binding	pIC50	=	7.3	7.3	-	0	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	127034614	136590	None	0	Human	Binding	pIC50	=	7.3	7.3	-	0	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	CHEMBL3736230	136590	None	0	Human	Binding	pIC50	=	7.3	7.3	-	0	Displacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysisDisplacement of Ac-[125I]-PACAP27 from recombinant human VPAC2 expressed in CHO cells after 90 mins by gamma counting analysis	ChEMBL	3246	105	48	45	-10.8	CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(C#Cc2ccccc2)cc1)C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)C)C(C)C)[C@@H](C)O	10.1016/j.ejmech.2015.09.017
	118334931	142529	None	0	Human	Binding	pIC50	=	5.2	5.2	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	11	3	7	2.8	CO[C@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
	CHEMBL3890096	142529	None	0	Human	Binding	pIC50	=	5.2	5.2	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	566	11	3	7	2.8	CO[C@H]1Cc2ccccc2[C@@H]1NC(=O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc2c(c1)OCCO2	nan
	118334909	149500	None	0	Human	Binding	pIC50	=	5.2	5.2	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	512	10	4	5	2.5	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(F)cc1	nan
	CHEMBL3945729	149500	None	0	Human	Binding	pIC50	=	5.2	5.2	-	0	Antagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assayAntagonist activity at recombinant human N-terminal signal peptide/FLAG epitope-tagged Rluc8-fused VIPR2 expressed in HEK293 cells assessed as inhibition of VIP-induced human mVenus-beta-arrestin2 binding preincubated for 5 mins with luciferin, coelenterazine H followed by VIP addition measured after 5 mins by BRET assay	ChEMBL	512	10	4	5	2.5	O=C(N[C@H]1c2ccccc2C[C@H]1O)[C@H](Cc1ccccc1)C[C@H](O)CNS(=O)(=O)c1ccc(F)cc1	nan
	3842	2436	None	0	Rat	Binding	pIC50	=	4.5	4.5	-	0	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	1155	3572	None	0	Rat	Binding	pIC50	=	4.5	4.5	-	2	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	16129665	3572	None	0	Rat	Binding	pIC50	=	4.5	4.5	-	2	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	3643	3572	None	0	Rat	Binding	pIC50	=	4.5	4.5	-	2	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	CHEMBL1201488	3572	None	0	Rat	Binding	pIC50	=	4.5	4.5	-	2	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	DB00021	3572	None	0	Rat	Binding	pIC50	=	4.5	4.5	-	2	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	3293	468	None	0	Rat	Binding	pIC50	=	5	5.0	-	0	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	3293	468	None	0	Human	Binding	pIC50	=	5.3	5.3	-	0	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	1155	3572	None	0	Human	Binding	pIC50	=	5.3	5.3	-	2	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	16129665	3572	None	0	Human	Binding	pIC50	=	5.3	5.3	-	2	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	3643	3572	None	0	Human	Binding	pIC50	=	5.3	5.3	-	2	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	CHEMBL1201488	3572	None	0	Human	Binding	pIC50	=	5.3	5.3	-	2	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	DB00021	3572	None	0	Human	Binding	pIC50	=	5.3	5.3	-	2	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	1152	3995	None	15	Human	Binding	pIC50	=	8.3	8.3	-5	4	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	16129679	3995	None	15	Human	Binding	pIC50	=	8.3	8.3	-5	4	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	53395115	3995	None	15	Human	Binding	pIC50	=	8.3	8.3	-5	4	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	91898389	3995	None	15	Human	Binding	pIC50	=	8.3	8.3	-5	4	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	CHEMBL1981592	3995	None	15	Human	Binding	pIC50	=	8.3	8.3	-5	4	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	1152	3995	None	15	Rat	Binding	pIC50	=	8.4	8.4	-	4	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	16129679	3995	None	15	Rat	Binding	pIC50	=	8.4	8.4	-	4	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	53395115	3995	None	15	Rat	Binding	pIC50	=	8.4	8.4	-	4	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	91898389	3995	None	15	Rat	Binding	pIC50	=	8.4	8.4	-	4	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	CHEMBL1981592	3995	None	15	Rat	Binding	pIC50	=	8.4	8.4	-	4	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	129887154	583	None	0	Human	Binding	pIC50	=	7.2	7.2	-	1	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	155817438	583	None	0	Human	Binding	pIC50	=	7.2	7.2	-	1	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16214732	583	None	0	Human	Binding	pIC50	=	7.2	7.2	-	1	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2269	583	None	0	Human	Binding	pIC50	=	7.2	7.2	-	1	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2281	583	None	0	Human	Binding	pIC50	=	7.2	7.2	-	1	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16133238	2990	None	0	Human	Binding	pIC50	=	7.7	7.7	-	3	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2257	2990	None	0	Human	Binding	pIC50	=	7.7	7.7	-	3	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	44134520	2990	None	0	Human	Binding	pIC50	=	7.7	7.7	-	3	inhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-PACAP-27 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	131850923	3077	None	0	Human	Binding	pIC50	=	5.5	5.5	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	155817437	3077	None	0	Human	Binding	pIC50	=	5.5	5.5	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	16154651	3077	None	0	Human	Binding	pIC50	=	5.5	5.5	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	2268	3077	None	0	Human	Binding	pIC50	=	5.5	5.5	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	131850923	3077	None	0	Rat	Binding	pIC50	=	5.7	5.7	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	155817437	3077	None	0	Rat	Binding	pIC50	=	5.7	5.7	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	16154651	3077	None	0	Rat	Binding	pIC50	=	5.7	5.7	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	2268	3077	None	0	Rat	Binding	pIC50	=	5.7	5.7	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9437716
	2266	2894	None	0	Human	Binding	pIC50	=	7.3	7.3	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	16133238	2990	None	0	Human	Binding	pIC50	=	7.6	7.6	-	3	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2257	2990	None	0	Human	Binding	pIC50	=	7.6	7.6	-	3	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	44134520	2990	None	0	Human	Binding	pIC50	=	7.6	7.6	-	3	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	1152	3995	None	15	Human	Binding	pIC50	=	7.7	7.7	-5	4	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	16129679	3995	None	15	Human	Binding	pIC50	=	7.7	7.7	-5	4	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	53395115	3995	None	15	Human	Binding	pIC50	=	7.7	7.7	-5	4	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	91898389	3995	None	15	Human	Binding	pIC50	=	7.7	7.7	-5	4	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	CHEMBL1981592	3995	None	15	Human	Binding	pIC50	=	7.7	7.7	-5	4	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2259	3346	None	0	Human	Binding	pIC50	=	8.7	8.7	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	2259	3346	None	0	Human	Binding	pIC50	=	8.7	8.7	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	2259	3346	None	0	Human	Binding	pIC50	=	8.7	8.7	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9145428
	1155	3572	None	0	Rat	Binding	pIC50	=	4.5	4.5	-	2	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16129665	3572	None	0	Rat	Binding	pIC50	=	4.5	4.5	-	2	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	3643	3572	None	0	Rat	Binding	pIC50	=	4.5	4.5	-	2	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	CHEMBL1201488	3572	None	0	Rat	Binding	pIC50	=	4.5	4.5	-	2	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	DB00021	3572	None	0	Rat	Binding	pIC50	=	4.5	4.5	-	2	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	1155	3572	None	0	Human	Binding	pIC50	=	5.3	5.3	-	2	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16129665	3572	None	0	Human	Binding	pIC50	=	5.3	5.3	-	2	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	3643	3572	None	0	Human	Binding	pIC50	=	5.3	5.3	-	2	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	CHEMBL1201488	3572	None	0	Human	Binding	pIC50	=	5.3	5.3	-	2	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	DB00021	3572	None	0	Human	Binding	pIC50	=	5.3	5.3	-	2	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	131850923	3077	None	0	Human	Binding	pIC50	=	5.7	5.7	-	0	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	155817437	3077	None	0	Human	Binding	pIC50	=	5.7	5.7	-	0	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	16154651	3077	None	0	Human	Binding	pIC50	=	5.7	5.7	-	0	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	2268	3077	None	0	Human	Binding	pIC50	=	5.7	5.7	-	0	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	2273	3109	None	0	Human	Binding	pIC50	=	7.5	7.5	-	0	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2273	3109	None	0	Rat	Binding	pIC50	=	7.5	7.5	-	0	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16133238	2990	None	0	Human	Binding	pIC50	=	8	8.0	-	3	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16133238	2990	None	0	Rat	Binding	pIC50	=	8	8.0	-	3	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2257	2990	None	0	Human	Binding	pIC50	=	8	8.0	-	3	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2257	2990	None	0	Rat	Binding	pIC50	=	8	8.0	-	3	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	44134520	2990	None	0	Human	Binding	pIC50	=	8	8.0	-	3	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	44134520	2990	None	0	Rat	Binding	pIC50	=	8	8.0	-	3	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2275	3113	None	0	Human	Binding	pIC50	=	8	8.0	-	0	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	1152	3995	None	15	Human	Binding	pIC50	=	8	8.0	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	1152	3995	None	15	Rat	Binding	pIC50	=	8	8.0	-	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	16129679	3995	None	15	Human	Binding	pIC50	=	8	8.0	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	16129679	3995	None	15	Rat	Binding	pIC50	=	8	8.0	-	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	53395115	3995	None	15	Human	Binding	pIC50	=	8	8.0	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	53395115	3995	None	15	Rat	Binding	pIC50	=	8	8.0	-	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	91898389	3995	None	15	Human	Binding	pIC50	=	8	8.0	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	91898389	3995	None	15	Rat	Binding	pIC50	=	8	8.0	-	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	CHEMBL1981592	3995	None	15	Human	Binding	pIC50	=	8	8.0	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	CHEMBL1981592	3995	None	15	Rat	Binding	pIC50	=	8	8.0	-	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	2275	3113	None	0	Rat	Binding	pIC50	=	8.2	8.2	-	0	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	1152	3995	None	15	Rat	Binding	pIC50	=	8.4	8.4	-	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16129679	3995	None	15	Rat	Binding	pIC50	=	8.4	8.4	-	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	53395115	3995	None	15	Rat	Binding	pIC50	=	8.4	8.4	-	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	91898389	3995	None	15	Rat	Binding	pIC50	=	8.4	8.4	-	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	CHEMBL1981592	3995	None	15	Rat	Binding	pIC50	=	8.4	8.4	-	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16132369	1918	None	0	Human	Binding	pIC50	=	8.5	8.5	-	1	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16132369	1918	None	0	Rat	Binding	pIC50	=	8.5	8.5	-	1	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2280	1918	None	0	Human	Binding	pIC50	=	8.5	8.5	-	1	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2280	1918	None	0	Rat	Binding	pIC50	=	8.5	8.5	-	1	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	53230038	1918	None	0	Human	Binding	pIC50	=	8.5	8.5	-	1	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	53230038	1918	None	0	Rat	Binding	pIC50	=	8.5	8.5	-	1	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2271	2895	None	0	Rat	Binding	pIC50	=	8.5	8.5	-	0	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	1152	3995	None	15	Human	Binding	pIC50	=	8.5	8.5	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	1152	3995	None	15	Human	Binding	pIC50	=	8.5	8.5	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	16129679	3995	None	15	Human	Binding	pIC50	=	8.5	8.5	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	16129679	3995	None	15	Human	Binding	pIC50	=	8.5	8.5	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	53395115	3995	None	15	Human	Binding	pIC50	=	8.5	8.5	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	53395115	3995	None	15	Human	Binding	pIC50	=	8.5	8.5	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	91898389	3995	None	15	Human	Binding	pIC50	=	8.5	8.5	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	91898389	3995	None	15	Human	Binding	pIC50	=	8.5	8.5	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	CHEMBL1981592	3995	None	15	Human	Binding	pIC50	=	8.5	8.5	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10570056
	CHEMBL1981592	3995	None	15	Human	Binding	pIC50	=	8.5	8.5	-5	4	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9928018
	2272	3078	None	0	Human	Binding	pIC50	=	8.7	8.7	-	0	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11068102
	2271	2895	None	0	Human	Binding	pIC50	=	9	9.0	-	0	inhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]Ro25 1553 binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9726637
	3842	2436	None	0	Human	Binding	pIC50	>	4.5	4.5	-	0	Inhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptorInhibition of [125I]VIP binding in membranes from CHO cells expressing recombinant receptor	Guide to Pharmacology		None	None	None		None	9437714
	3842	2436	None	0	Human	Binding	pIC50	>	6	6.0	-	0	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11931347
	129887154	583	None	0	Human	Binding	pKd	=	9.2	9.2	-	1	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	155817438	583	None	0	Human	Binding	pKd	=	9.2	9.2	-	1	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16214732	583	None	0	Human	Binding	pKd	=	9.2	9.2	-	1	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2269	583	None	0	Human	Binding	pKd	=	9.2	9.2	-	1	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	2281	583	None	0	Human	Binding	pKd	=	9.2	9.2	-	1	binding to membranes from CHO cells stably expressing the recombinant receptorbinding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	11978642
	16132300	218808	125I-VIP	0	Rat	Binding	pKi	=	9.4	9.4	-1	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	16132300.0	218808	125I-VIP	0	Rat	Binding	pKi	=	9.4	9.4	-1	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	53314964	218808	125I-VIP	0	Rat	Binding	pKi	=	9.4	9.4	-1	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	CHEMBL1981592	218808	125I-VIP	0	Rat	Binding	pKi	=	9.4	9.4	-1	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	16132300	218808	125I-VIP	0	Human	Binding	pKi	=	8.7	8.7	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	16132300.0	218808	125I-VIP	0	Human	Binding	pKi	=	8.7	8.7	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	53314964	218808	125I-VIP	0	Human	Binding	pKi	=	8.7	8.7	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	CHEMBL1981592	218808	125I-VIP	0	Human	Binding	pKi	=	8.7	8.7	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	16132300	218808	125I-VIP	0	Rat	Binding	pKi	=	8.7	8.7	-1	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	16132300.0	218808	125I-VIP	0	Rat	Binding	pKi	=	8.7	8.7	-1	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	53314964	218808	125I-VIP	0	Rat	Binding	pKi	=	8.7	8.7	-1	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	CHEMBL1981592	218808	125I-VIP	0	Rat	Binding	pKi	=	8.7	8.7	-1	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	16132300	218808	125I-VIP	0	Human	Binding	pKi	=	8.3	8.3	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	16132300.0	218808	125I-VIP	0	Human	Binding	pKi	=	8.3	8.3	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	53314964	218808	125I-VIP	0	Human	Binding	pKi	=	8.3	8.3	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	CHEMBL1981592	218808	125I-VIP	0	Human	Binding	pKi	=	8.3	8.3	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	16132300	218808	125I-VIP	0	Human	Binding	pKi	=	8.2	8.2	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	16132300.0	218808	125I-VIP	0	Human	Binding	pKi	=	8.2	8.2	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	53314964	218808	125I-VIP	0	Human	Binding	pKi	=	8.2	8.2	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	CHEMBL1981592	218808	125I-VIP	0	Human	Binding	pKi	=	8.2	8.2	-5	3	NoneNone	PDSP KiDatabase	3325	113	51	48	-14.6	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC4=CNC=N4)N	None
	1152	3995	None	15	Human	Binding	pKi	=	7.8	7.8	-5	4	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	16129679	3995	None	15	Human	Binding	pKi	=	7.8	7.8	-5	4	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	53395115	3995	None	15	Human	Binding	pKi	=	7.8	7.8	-5	4	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	91898389	3995	None	15	Human	Binding	pKi	=	7.8	7.8	-5	4	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	CHEMBL1981592	3995	None	15	Human	Binding	pKi	=	7.8	7.8	-5	4	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	2276	3345	None	0	Human	Binding	pKi	=	8	8.0	316	2	inhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9152366
	2278	328	None	0	Human	Binding	pKi	=	5.6	5.6	-316	2	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	1152	3995	None	15	Human	Binding	pKi	=	8.8	8.8	-5	4	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	16129679	3995	None	15	Human	Binding	pKi	=	8.8	8.8	-5	4	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	53395115	3995	None	15	Human	Binding	pKi	=	8.8	8.8	-5	4	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	91898389	3995	None	15	Human	Binding	pKi	=	8.8	8.8	-5	4	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	CHEMBL1981592	3995	None	15	Human	Binding	pKi	=	8.8	8.8	-5	4	inhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from CHO cells stably expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	10801840
	1152	3995	None	15	Human	Binding	pKi	=	8.7	8.7	-5	4	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
	16129679	3995	None	15	Human	Binding	pKi	=	8.7	8.7	-5	4	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
	53395115	3995	None	15	Human	Binding	pKi	=	8.7	8.7	-5	4	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
	91898389	3995	None	15	Human	Binding	pKi	=	8.7	8.7	-5	4	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823
	CHEMBL1981592	3995	None	15	Human	Binding	pKi	=	8.7	8.7	-5	4	inhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptorinhibition of [125I]-VIP binding to membranes from COS cells transiently expressing the recombinant receptor	Guide to Pharmacology		None	None	None		None	9454823

Join us

Cite us

Main reference

Ligand source activities (1 row/activity)